APA (7th ed.) Citation

Conteduca, V., Brighi, N., Gurioli, G., Wetterskog, D., Giunta, E., Lolli, C., . . . De Giorgi, U. (2024). LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study). Annals of Oncology, 35, S1259. https://doi.org/10.1016/j.annonc.2024.08.2314

Chicago Style (17th ed.) Citation

Conteduca, V., et al. "LBA71 Open-label, Multicentre Randomised Trial of Radium223-docetaxel Versus Docetaxel-Radium223 Sequence in Metastatic Castration Resistant Prostate Cancer (mCRPC) with Prospective Biomarker Evaluation (RAPSON Study)." Annals of Oncology 35 (2024): S1259. https://doi.org/10.1016/j.annonc.2024.08.2314.

MLA (9th ed.) Citation

Conteduca, V., et al. "LBA71 Open-label, Multicentre Randomised Trial of Radium223-docetaxel Versus Docetaxel-Radium223 Sequence in Metastatic Castration Resistant Prostate Cancer (mCRPC) with Prospective Biomarker Evaluation (RAPSON Study)." Annals of Oncology, vol. 35, 2024, p. S1259, https://doi.org/10.1016/j.annonc.2024.08.2314.